Since the patients with double‐hit and triple‐hit lymphomas were excluded from this study, it was speculated that identifying the DDX3X mutations at the time of relapse might be valuable for evaluating the prognosis of rrDLBCL patients. The gene discussed is DDX3X; the disease is lymphoma.